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Abstract
Background: Infection w ith Human Papillomavirus (HPV) is a necessary event in the m ulti-step process o f cervical 
carcinogenesis. Little is known about the natural history o f HPV infection among unscreened young adults. As prophylactic 
vaccines are being developed to  prevent specifically HPV 16 and 18 infections, shifts in prevalence in the post vaccine era 
may be expected. This study provides a unique opportun ity  to  gather baseline data before changes by nationwide 
vaccination occur.
Methods and Principal Findings: This cross-sectional study is part o f a large prospective epidem iologic study performed 
among 2065 unscreened women aged 18 to  29 years. Women returned a self-collected cervico-vaginal specimen and filled 
out a questionnaire. All HPV DNA-positive samples (by SPF10 DEIA) were genotyped using the INNO-LiPA HPV genotyping 
assay. HPV point prevalence in this sample was 19%. Low and high risk HPV prevalence was 9.1% and 11.8%, respectively. A 
single HPV-type was detected in 14.9% o f all women, while m ultiple types were found in 4.1%. HPV-types 16 (2.8%) and 18 
(1.4%) were found concom itantly in only 3 women (0.1%). There was an increase in HPV prevalence till 22 years. Multivariate 
analysis showed that number o f lifetime sexual partners was the most powerful predictor o f HPV positivity, followed by type 
o f relationship, frequency o f sexual contact, age, and number o f sexual partners over the past 6  months.
Conclusions and Significance: This study shows that factors independently associated w ith  HPV prevalence are mainly 
related to  sexual behaviour. Combination o f these results w ith  the relative low prevalence o f HPV 16 and/or 18 may be 
promising for expanding the future target group for catch up vaccination. Furthermore, these results provide a basis for 
research on possible future shifts in HPV genotype prevalence, and enable a better estimate o f the effect o f HPV 16-18 
vaccination on cervical cancer incidence.
Citation: Lenselink CH, Melchers WJG, Quint WGV, Hoebers AMJ, Hendriks JCM, et al. (2008) Sexual Behaviour and HPV Infections in18  to 29 Year Old Women in 
the Pre-Vaccine Era in the Netherlands. PLoS ONE 3(11): e3743. doi:10.1371/journal.pone.0003743
Editor: Torbjorn Ramqvist, Karolinska Institutet, Sweden
Received August 13, 2008; Accepted October 9, 2008; Published November 17, 2008
Copyright: © 2008 Lenselink et al. This is an open-access article distributed under the terms o f the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: GlaxoSmithKline (GSK 2702-HPV-109932 to R.L.B, L.F.M.). The funder had no role in study design, data collection and analysis, decision to  publish, or 
preparation o f the manuscript.
C om peting Interests: The authors have declared that no competing interests exist.
*  E-mail: c.lenselink@obgyn.umcn.nl
Introduction
Upcoming mass vaccination with H um an Papillomavirus (HPV) 
vaccines will most certainly change HPV  epidemiology. Monitor­
ing these changes on population level may prove crucial in 
assessing the effect of mass vaccination and overall HPV vaccine 
efficacy. In the Netherlands, girls aged 12 years will be vaccinated 
as of September 2009, and the catch-up vaccination (girls aged 13 
to 16 years) will probably start in the first part of 2009.
Until now, only a limited number of large studies have 
investigated HPV  epidemiology in female adolescents and young 
female adults. Even fewer studies have investigated HPV 
epidemiology in relation to past en present sexual behaviour.
Genital infection with the H um an Papillomavirus (HPV) is the 
most common sexually transmitted infection (STI) among young 
sexually active women [1]. Most sexually active women (>50%) 
have been genitally infected by one or more HPV types at some 
point in their life [2]. Fourteen HPV genotypes are associated with
cervical cancer development and are therefore called high-risk (hr- 
HPV). O f these hr-HPV genotypes, hr-HPV 16 and 18 are related 
to 70% of all cervical cancers. Therefore, prophylactic vaccines 
against these two HPV types have been developed. It has been 
estimated that the best results of prophylactic vaccination will be 
achieved by vaccinating women before they become genitally 
infected i.e. sexually active. Presently, vaccination programs are 
being started in many countries around the world, targeting 9 to 16 
year old girls [3,4]. Additionally, catch-up vaccination of already 
sexually active women is under consideration in many countries in 
order to get a faster decrease in cervical cancer incidence.
Estimates of HPV infections among asymptomatic women 
around the world range from 2% to 44% [5-8]. The wide 
variation in prevalence is largely explained by differences in 
sensitivity of the HPV-DNA assay used, differences in age, or 
differences in other characteristics of the populations studied [2,7].
Additionally, little is known about risk factors for acquiring 
genital HPV in young female adults. Therefore, further assessment
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of risk factors like sexual behaviour is important. Knowledge of 
baseline, i.e. pre-vaccination, epidemiology of type specific HPV 
infections in relation to sexual behaviour is im portant in order to 
decide whether catch-up vaccination may be beneficial. After 
nationwide implementation of the prophylactic HPV vaccine, 
HPV epidemiology will most likely change due to expected 
decreases in HPV 16-18 prevalence and incidence, as well as 
possible changes in other types occurring due to cross protection of 
the vaccine. Due to these shifts, prevalence and incidence of other 
HPV types may increase and therefore may change the 
oncogenicity of these types.
Therefore, this study, conducted before the nationwide 
introduction of HPV vaccines, provides a unique opportunity to 
determine baseline data on HPV prevalence in 18 to 29 year old 
women in the Netherlands. Additionally, no regular cervical 
cancer screening is performed in this age group, as the Cervical 
Screening Program starts at the age of 30 years. This study is part 
of a large prospective epidemiologic study conducted to study the 
dynamics of HPV infections, in particular HPV 16/18, and to get 
more insight in specific risk factors for acquiring genital HPV, like 
past and present sexual behaviour. These results provide a basis 
for understanding possible future shifts in genotypes, and 
presumably enable a better estimate of the effect of HPV 16/18 
vaccination on cervical cancer incidence.
Methods
Study population and study design
This cross-sectional study is part of a large prospective 
epidemiologic study performed among 2065 unscreened women 
aged 18 to 29 years. W omen were recruited between June and 
September 2007, using different advertisements, as well as active 
recruitment sites, and posters at general practices in the city 
regions of Arnhem, Nijmegen, and Den Bosch, the Netherlands. 
Furthermore, advertisement on the internet were used, which were 
accessible in the whole of the Netherlands. O f the 2297 women 
who responded to the advertisements, 2065 (89.9%) consented 
with the study, returned the cervico-vaginal swab specimens, and 
filled out the questionnaire. W ritten informed consent was 
obtained from all participants. This study was approved by the 
Local Medical Ethics Committee.
Specimen Collection and Processing
All women were asked to fill out a questionnaire and to self-collect 
a cervico-vaginal sample in the privacy of their own home. Women 
received an explanatory letter, an informed consent form, a 
questionnaire, and a self-sample kit by mail. The self sample kit 
contained a collection device (a small brush packaged in an individual 
sterile cover, Vibabrush®, Rovers Medical Devices Oss, the Nether­
lands), a collection tube containing medium (SurePathtm, Tripath 
Imaging®, Inc., Burlington NC, U.S.A.), instructions how to perform 
the cervico-vaginal self-sample (written and in cartoon), and a return 
package consisting of a leak-proof seal bag, absorption sheet, and a 
reclosable plastic return envelope (easyslider, Transposafe Systems 
Holland BV). In brief, participants were instructed to wash their 
hands before opening the brush cover, to hold the brush by the end of 
the handle, to insert the brush approximately 7 cm into the vagina 
(similar to inserting a tampon), to gently turn the brush 5 times, and to 
place the top of the brush in the collection tube. The collection tube 
was closed, and enclosed in the seal-bag. Finally, the collection tube 
was placed in the return envelope, together with the questionnaire, 
and sent to the Department of Obstetrics and Gynaecology for 
further processing and HPV assessment. The samples were stored at 
room temperature.
T ab le  1. HPV prevalence by demographic variables among all 
women.
Sample  
size (n)
HPV
Prevalence (n) P value*
Overall 2065 393 (19.0%) -
Age (in years) <0.001*
18 142 12 (8.5%)
19 173 19 (11.0%)
20 190 24 (12.6%)
21 185 30 (16.2%)
22 187 41 (21.9%)
23 185 24 (13.0%)
24 186 43 (23.1%)
25 182 44 (24.2%)
26 186 41 (22.0%)
27 168 52 (31.0%)
28 172 37 (21.5%)
29 109 26 (23.9%)
Ethnicity0 2050 0.73*
Dutch 1981 378 (19.1%)
Other 69 12 (17.4%)
E du catio n ' 2044 0.424*
Lower secondary/Lower 
vocational training
71 13 (18.3%)
Higher Secondary/Vocational 
training
428 72 (16.8%)
Higher vocational training/ 
University
1545 303 (19.6%)
Current smoking 2054 <0.001*
Yes 406 114 (28.1%)
No 1648 277 (16.8%)
Using OCC 2061 0.758*
Yes 1459 275 (18.8%)
No 602 117 (19.4%)
Living w ith  parents 2052 0.008*
Yes 357 59 (14.0%)
No 1695 340 (20.1%)
Relationship 2053 <0.001*
Married 125 7 (5.6%)
Living together 483 73 (15.1%)
LAT“ 823 177 (21.5%)
Single 622 134 (21.5%)
Sexual activity ever <0.001*
Yes 1947 389 (20%)
No 116 4 (3.4%)
HPV+ if one or more genotypes(high risk as well as low risk) are detected 
simultaneously.
Sample sizes change because o f missing values o f the questionnaire. 
n = number.
- not applicable.
*by Chi-square test.
#  ethnicity was self-reported.
'ty p e  o f education: group o f lower secondary education includes 2 women 
who reported only primary/no education.
“ Living apart together.
OCC oral contraceptives. 
doi:10.1371/journal.pone.0003743.t001
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Questionnaire
In this study we used a questionnaire consisting of two parts. 
The first part was composed of questions regarding socio­
demographic variables like educational level, religion, smoking, 
medication use, contraceptive use, and ethnicity. Race and 
ethnicity were self-reported into different categories. The second 
part consisted of questions regarding sexual behaviour to gain 
insight in risk factors for acquiring genital HPV. Results of HPV 
detection were correlated to past and present sexual behaviour. 
Sex was defined as vaginal, oral, an d /o r anal sex. For women who 
had at least 1 lifetime sex partner, additional questions were asked 
on age at first sexual contact, age of first sex partner, number of 
sex partners before the age of sixteen, lifetime number of sex 
partners, number of sex partners in the past 6 months, gender of 
sex partners, frequency of sexual contact, condom use, and history 
of sexually transmitted infections (STI).
HPV DNA Detection and Genotyping
Broad-spectrum HPV DNA amplification was performed using 
a short PCR fragment assay (SPF10-LiPA HPV detection/ 
genotyping assay, SPF10 system version 1, manufactured by Labo 
Biomedical Products bv, Rijswijk, The Netherlands). This assay 
amplifies a 65-bp fragment of the L1 open reading frame and 
allows detection of at least 43 different HPV  types [9-12]. The 
SPF10 PCR was performed with a final reaction volume of 50 ml 
containing 10 ml of the isolated DNA sample, 10 m m ol/liter Tris- 
H Cl (pH 9.0), 50 mm ol/liter KCl, 2.0 mm ol/liter M gCl2, 0.1% 
Triton X-100, 0.01% gelatin, 200 mmol/liter of each deoxynu- 
cleoside triphosphate, 15 pmol each of the forward and reverse 
primers tagged with biotin at the 5'end, and 1.5 U of AmpliTaq 
Gold (Perkin-Elmer). The mixture was incubated for 9 minutes at 
94°C, 40 cycles of 45 s at 45°C, and 40 cycles of 45 s at 72°C, with 
a final extension of 5 minutes at 72°C. Each experiment was
Figure 1. 95%  Confidence Interval of HPV Prevalence by Age (n = 2065). There was an overall increase in HPV prevalence with age till 22 
years, afterwards a plateau phase was reached. A decrease is shown at 23 years and a peak among women aged 27 years, however, as the 95% 
confidence interval is overlapping with adjacent age groups, the differences were considered accidental findings. 
doi:10.1371/journal.pone.0003743.g001
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performed with a separate positive and negative PCR control. The 
presence of HPV  DNA was determined by hybridization of SPF10 
amplimers to a mixture of general HPV  probes recognizing a 
broad range of HPV genotypes, in a microtiter plate format, as 
described previously [9-12].
All HPV  DNA-positive samples (by SPF10 DEIA) were 
genotyped using the INNO-LiPA HPV  genotyping assays.
The 28 oligonucleotide probes that recognize 25 different types 
were tailed with poly(dT) and immobilized as parallel lines to 
membrane strips (Labo Bio-Medical Products B.V., Rijswijk, The 
Netherlands). The HPV genotyping assay was performed as 
described previously [9]. Samples that tested positive using the 
DNA enzyme immunoassay but that showed no results on the 
LiPA strip were considered to be HPV X  type, i.e. genotypes not 
available on the LiPA strip. Low risk HPV  (lr-HPV) types were 
defined as HPV  type 6,11, 34, 40, 42, 43, 44, 53, 54, 55, 58, 66,
70, 74, and ‘‘X ’’; and hr-HPV types as HPV  16, 18, 31, 33, 35, 39, 
45, 51, 52, 56, 59, 68, 73, and 82.
Statistical Analysis
All women who completed the questionnaire and submitted a swab 
for HPV evaluation were included in the final analysis (n = 2065).
The Chi-Square test was used to test associations between 
demographic variables or behavioural characteristics and HPV. 
Differences of medians of continuous variables between the groups 
were analysed using non-parametric tests (Mann-Whitney).
In univariate and multivariate analysis, data ofsome variables were 
grouped due to small numbers and /o r to gain a better overview. We 
grouped ethnicity into two groups: Dutch and not Dutch. Lifetime 
number of partners and number of partners in the past six months 
were divided into four categories, and frequency of sexual contact was 
grouped into five categories. Years of being sexually active (i.e. sexual
Figure 2. A. Prevalence of Low-Risk and High-Risk Types by Age (n = 2065). Prevalence of overall and both hr- and lr-HPV types showed an 
almost similar age-distribution. In some women both low-risk and high-risk types were detected. B. Prevalence of Low-Risk and High-Risk 
Types by Sexual Age (n = 1943). Only sexually active women were selected (n=1943). Overall HPV prevalence, as well as hr- and lr-HPV 
prevalence, showed an increase with rising sexual age. However, hr-HPV prevalence decreased from a sexual age of 10 years. In some women both 
low-risk and high-risk types were detected. 
doi:10.1371/journal.pone.0003743.g002
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age) ranged from 0 to 23 years, the category ‘‘0’’ years consisted of 
women who became sexually active in the past year. Because of the 
small numbers, 0 and 1 year were combined as well as 13 to 23 years. 
Chlamydia, genital warts, Syphilis, Gonorrhea, Genital Herpes, and 
HIV were defined as STI. In further statistical analysis previous STI’s 
were defined as yes or no.
Variables found to be significantly related to HPV infection by 
univariate analyses were entered into a multiple logistic regression 
model with forward selection procedures to identify variables that 
contributed independently to the probability of HPV  prevalence.
Participants with missing data on variables included in the 
multivariate analysis were excluded. In all tests, p values <0.05 
were regarded statistically significant.
Statistical analyses were performed using SAS (8.0) and SPSS 
14.1 (Chicago, Illinois).
Results
Socio-demographic characteristics
The age distribution and socio-demographic characteristics of 
the 2065 participants are summarised in table 1. Many women
Figure 3A Prevalence High-Risk HPV Types
H
D „ 1
16 18 31 33 35 39 45 51 52 56 59 68 73 82 
High risk HPV genotype
Note: in some women both low-risk and high-risk types were detected.
Figure 3B Prevalence Low-Risk HPV Types
b .D
r1 ,o
n
1 .  . n ■  -
6 11 34 40 42 43 44 53 54 55 58 66 70 74 
Low risk HPV genotype
Note: In some women both low-risk and high-risk types were detected.
HPV genotype 53 and 66 can also be considered as possible high risk types
Figure 3. A. Prevalence High-Risk HPV Types. Most common types detected were HPV type 16 (2.8%, n = 57), HPV type 51 (2.5%, n = 51), and 
HPV type 52 (2.5%, n = 52). In some women both low-risk and high-risk types were detected. B. Prevalence Low-Risk HPV Types. In some women 
both low-risk and high-risk types were detected. HPV genotype 53 and 66 can also be considered as possible high risk types. 
doi:10.1371/journal.pone.0003743.g003
attended higher vocational training or University in past or 
presence (n=  1545, 75.6%). O f all women, 622 (30.3%) were 
single and 1431 (69.7%) were involved in a relationship. Only 69 
women (3.4%) reported an ethnicity other than Dutch, including 
‘‘other European’’ 1.1% (n = 23), Caribbean 0.7% (n=15), 
Turkish 0.2% (n = 4), Asian 0.6% (n = 12), African 0.2% (n = 3), 
and ‘‘other’’ 0.6% (n=  12). Because of these small numbers, they 
were divided into two groups: Dutch (96.6%, n=1981), and 
‘‘other’’ (3.4%, n = 69).
Additionally, the mean age at first sexual contact was 16.7 years, 
and the mean sexual age (i.e. years of being sexually active) was 6.8 
years. W omen who were not sexually active yet were significantly 
more often living with their parents (11.5%, n = 41 versus 4.4%, 
n = 75, p = <0.001, data not shown).
Prevalence of HPV infection
O f the 2065 adequate specimens, 19% (n = 393) tested positive 
for one or more HPV  genotypes. Age-specific prevalence is shown 
in table 1. There was an overall increase in HPV  prevalence with 
age till 22 years, afterwards a plateau phase was reached. 
Prevalence of HPV  infection showed a decrease at 23 years and
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T ab le  2. HPV prevalence and Odds Ratio's for HPV prevalence among sexually active women using univariate analysis and logistic 
regression.
n HPV+ p OR (95%  C.I.) p
n (% )/M edian (range)
Age (years) 1947 25 (18-29) <0.001 ' 1.097 (1.059;1.136) <0.001
Current smoking 1936 <0.001*
No 1536 274 (17.8%) 0.551 (0.428;0.711) <0.001
Yes 400 113 (28.3%) 1 (ref)
Using OCC 1944 0.272*
No 528 114 (21.6%) 1.148 (0.898;1.467) 0.272
Yes 1416 274 (19.4%) 1 (ref)
Living w ith  parents 1934 0.022*
No 1619 398 (20.9%) 1.468 (1.055;2.041) 0.023
Yes 315 48 (15.2%) 1 (ref)
Relationship 1935 <0.001*
Married 125 7 (5.6%) 0.216 (0.099;0.471) <0.001
Living together 483 73 (15.1%) 0.647 (0.480;0.874) 0.004
Single 511 131 (25.6%) 1.254 (0.967;1.625) 0.088
LATn 816 176 (21.6%) 1 (ref)
Age at first intercourse** (years) 1944 0.053*
#13 45 13 (28.8%) 1.517 (0.719;3.204) 0.274
14-16 935 203 (21.7%) 1.036 (0.688;1.560) 0.866
17-19 803 139 (17.3%) 0.782 (0.514;1.190) 0.251
$20 161 34 (21.1%) 1 (ref)
Lifetim e sex partners (number) 1938 <0.001*
1 1 7 (4.2%) 0.044 (0.025;0.077) <0.001
2-5 136 (14.7%) 0.173 (0.125;0.239) <0.001
6-10 127 (32%) 0.470 (0.334;0.662) <0.001
>10 107 (50%) 1 (ref)
Gender o f sex partner(s) 1939 <0.001*
Male 1829 349 (19.1) 0.393 (0.260;0.594) <0.001
Female 6 0 (0%) 0.000 (0.000; .) 0.999
Both 104 39 (37.5%) 1 (ref)
Sex partners in past 6  months  
(number)
1939 <0.001*
0 170 22 (12.9%) 0.140 (0.077;0.254) <0.001
1 1485 249 (16.8%) 0.190 (0.125;0.288) <0.001
2 188 66 (35.1%) 0.509 (0.310;0.835) 0.008
> 2 99 51 (51.1%) 1 (ref)
Sexual contact in past 6 months 
(frequency)
1886 <0.001*
0 146 19 (13%) 0.461 (0.274;0.775) 0.003
1-6 221 66 (29.9%) 1.312 (0.927;1.857) 0.125
7-24 239 47 (19.7%) 0.754 (0.519;1.096) 0.139
25-54 729 111 (15.2%) 0.553 (0.418;0.732) <0.001
>54 551 135 (25.4%) 1 (ref)
Ever diagnosed a STI°? 1940 <0.001*
No 1755 315 (17.9%) 0.355 (0.257;0.488) <0.001
Yes 186 71 (38.2%) 1 (ref)
Condom use 1938 <0.001*
Never (0%) 924 142 (15.4%) 1.005 (0655;1.541) 0.983
Sometimes (0-50%) 499 134 (26.9%) 2.031 (1.313;3.143) 0.001
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T ab le  2. cont.
n HPV+ p OR (95%  C.I.) p
n (% )/M edian (range)
Most o f times (50-100%) 318 82 (25.8%) 1.923 (1.210;3.055) 0.006
Always (100%) 197 30 (15.2%) 1 (ref)
Sexual Age (years) % 1943 8 (1-13) < 0 .0 0 1 ' 1.096 (1.061;1.133) <0.001
HPV+ if one or more genotypes are detected simultaneously.
Sample sizes change because o f missing values o f the questionnaire. 
n = number.
95% C.I. Confidence Interval. 
p: p-value.
'M a n n  Whitney.
*by Chi-square test.
Ref: reference.
OCC oral contraceptives.
“ Living apart together.
**below the age o f 10 years several cases o f sexual abuse were reported.
STI, Sexually Transmitted Infection.
%Sexual age in years w ith 0 and 1 combined as well as sexual age higher than 13. 
doi:10.1371/journal.pone.0003743.t002
a peak among women aged 27 years (13%, n = 24, and 31%, 
n = 52, respectively). However, as the 95% confidence interval was 
overlapping with adjacent age groups, the differences were 
considered accidental findings (see Figure 1).
The overall prevalence of hr-HPV types was 11.8% and of lr- 
HPV  types 9.1%, including co-infections. Prevalence of both hr- 
and lr-HPV types showed an almost similar age-distribution (see 
Figure 2A).
Prevalence of specific HPV genotypes
A single HPV-type was detected in 14.9% of all women, while 
multiple types were found in 4.1% (21.6% of all HPV-positive 
women). We identified 25 different genotypes, most common types 
detected were HPV type 16 (2.8%, n = 57), HPV type 51 (2.5%, 
n = 51), and HPV type 52 (2.5%, n = 52). HPV  types 18, 6, and
11, were detected in 1.4% (n = 28), 0.6% (n=12), and 0.2% 
(n = 4), respectively (see Figure 3A and 3B). In 3.5% of the women 
the HPV  type could not be specified and was named Lipa X  
(n = 72). A simultaneous presence of HPV  16 and 18 only occurred 
in 3 women (0.1%). HPV  DNA was detected in 4 women who 
reported never having had sex. It concerned single infections with 
HPV  type 52, two times HPV type 16, and a co-infection with 
HPV  type 66 and 33.
Sexually active women
W hen univariate analysis was restricted to sexually active 
women, factors significantly associated with HPV prevalence were 
increasing age, current smoking, number of partners in the past 6 
months, and years of being sexually active (i.e. sexual age) (see 
Table 2 and Figure 2B). Sexual age was defined as time interval in 
years between age at first sexual contact and current age. 
Furthermore, a higher number of lifetime sexual partners, was 
significantly associated with overall HPV prevalence as well as hr- 
HPV  prevalence (see Table 2 and Figure 4). W omen without an 
HPV  infection tended to be married or living together with their 
partner. Age at first sexual contact did not show a significant 
relationship with current HPV prevalence (see Table 2). HPV 
prevalence, as well as hr- and lr-HPV prevalence, showed an 
increase with rising sexual age (see Table 2 and Figure 2B). 
However, hr-HPV prevalence decreased from a sexual age of 10
years (see Figure 2B). Oral contraceptive (OCC) use could not be 
defined as a risk factor for HPV  positivity.
After logistic regression, age, smoking, number of sexual 
partners (lifetime and in past 6 months), type of relationship, 
living with parents, and sexual age were significantly associated 
with HPV prevalence. Additionally, HPV prevalence was lower 
among women without a previous STI (Odds Ratio (OR) 0.355, 
p<0.001, see Table 2), but there was no significant difference 
between the type of ST I’s. W omen who reported to be non­
smokers tested significantly less often positive for HPV than 
women who reported to be current smokers (17.8% versus 28.3%, 
O R  0.551, p<0.001, see Table 2). W omen not living with their 
parents tested significantly more often positive for HPV  than 
women who were living with their parents (20.9% versus 15.2%, 
O R  1.468, 95% C.I. 1.055;2.041, p = 0.02). Age at first sexual 
intercourse was not significantly related to HPV  prevalence, 
whereas sexual age was (p = 0.053, and p<0.001, respectively).
The analysis was concluded by completing a multivariate 
regression analysis on all factors that showed a significant relation 
with HPV in the univariate analysis. The factors independently 
associated with a risk of being HPV positive were, with an 
exception for age, mainly related to sexual behaviour (see Table 3). 
The number of lifetime sexual partners was the most powerful 
independent predictor of HPV prevalence (p<0.001). Followed by 
type of relationship (p<0.001), with a significant difference 
between being married /  living together and having a relationship 
but living apart. This was followed by frequency of sexual contact 
(p = 0.001), age (p<0.001), and number of sexual partners in past
6 months (p = 0.018), with a protective effect of having a single 
partner. Sexual age (p = 0.022) was also independently associated 
with HPV prevalence. Additionally, condom use was not defined 
as an independent risk factor as it was dependant on age, type of 
relationship, frequency of sexual contact, and number of sexual 
partners in the past six months.
Discussion
This is the first Dutch HPV epidemiological study conducted 
among unscreened women aged 18 to 29 years. The point 
prevalence of HPV DNA in this sample was 19%. Lr- and hr-HPV
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Figure 4. Num ber of lifetim e sexual partners by High-Risk HPV. A higher number o f lifetime sexual partners, was significantly associated with
overall HPV prevalence as well as hr-HPV prevalence.
doi:10.1371/journal.pone.0003743.g004
prevalence were 9.1% and 11.8%, respectively. H r-H PV  types 16 
(2.8%) and 18 (1.4%) were found concomitantly in only 3 women 
(0.1%). These results are comparable with recent studies among 
young women, although different sampling methods were used 
[8,13-15]. In  this large study, self-collected cervico-vaginal 
samples were used. Material from self-sampling brushes or vaginal 
lavages has been proven to be highly representative for the cervical 
HPV  status [16]. HPV point prevalence was linked to sexual 
behaviour by using questionnaires. As the questionnaires were 
only provided with a study number, they could be considered as 
fairly anonymous, inducing high credibility. The number of sexual 
partners, as well as the type of current relationship were 
significantly associated with HPV positivity. Several international 
studies confirm sexual behaviour and a high number of sexual 
partners as the most im portant risk factors to contract STI’s 
[5,15,17-22]. In this study not only the number of sexual partners 
in the past six months but also number of lifetime sexual partners 
was independently associated with a higher risk for HPV 
prevalence. An active HPV infection is likely to be dependent 
on recent sexual activity and may therefore be acquired recently, 
whereas latent or persistent infection could be influenced by past 
sexual behaviour. A higher number of lifetime sexual partners
increases the risk of getting infected with one or more HPV  types 
in time. Every HPV infection has its type dependent clearance 
which takes 8 to 14 months on average. Women, who have not 
been sexually active recently, i.e. in the past six months, may test 
positive for HPV. Another explanation for the influence of the 
sexual past is that latent infections are detected. Detecting a latent 
infection is dependent on the sensitivity of the technique used. In 
this study the highly sensitive HPV genotyping test SPF10-LIPA is 
used, which could make it difficult to discriminate between active 
(i.e. chronic productive infections) and latent infections because of 
its low threshold value. Therefore, results of this study, showing 
point prevalences of HPV infections, may be a mixture of latent 
and active or persistent infections.
Furthermore, multivariate analysis provided insight in the 
independent risk factors for prevalent HPV  infection. The 
independent risk factors were all related to sexual behaviour, with 
the exception for age. We found that HPV  prevalence increased 
with age. Studies often show HPV  prevalence decreasing towards
30 years. This may be explained by the fact that the Dutch 
Cervical Screening Program starts at the age of 30 years, and 
therefore these women are unscreened. Furthermore, we did not 
study women above the age of 29, and we did not combine
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T ab le  3. Adjusted Odds Ratio's for HPV prevalence among 
sexually active women using multivariate logistic regression 
(n = 1820).
Adj. OR (95%  C.I.) p
Age (years) 1.160 (1.081;1.246) <0.001
Relationship <0.001
Married 0.227 (0.098;0.525) 0.001
Living together 0.565 (0.397;0.801) 0.001
Single 1.037 (0.685-1.570) 0.864
LAT“ 1 (ref)
Lifetim e sex partners
(number)
<0.001
1 0.061 (0.031;0.117) <0.001
2-5 0.208 (0.139;0.313) <0.001
6-10 0.512 (0.350;0.748) <0.001
>10 1 (ref)
Sex partners in past 6 
m onths (number)
0.018
0 0.153 (0.009;2.723) 0.201
1 0.467 (0.278;0.784) 0.004
2 0.674 (0.389;1.169) 0.160
> 2 1 (ref)
Sexual contact in past 6 
m onths (frequency)
0.001
0 1.218 (0.073;20.232) 0.886
1-6 0.701 (0.431;1.142) 0.160
7-24 0.541 (0.345;0.848) 0.008
25-54 0.513 (0.375;0.703) <0.001
>54 1 (ref)
Sexual Age (years) % 0.917 (0.851;0.988) 0.022
n = number.
95% C.I. Confidence Interval. 
p: p-value.
“ Living apart together.
Ref: reference.
uSTI, Sexually Transmitted Infection.
%Sexual age in years w ith 0 and 1 combined as well as sexual age higher than 
13.
doi:10.1371/journal.pone.0003743.t003
different age groups, which may provide another perspective by 
leveling the differences. O ther explanations could be the 
techniques used or differences in the population studied. The
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